NeuBase Therapeutics, Inc. recently filed a Form 15-12G with the Securities and Exchange Commission (SEC), signaling its termination of registration under Section 12(g) of the Securities Exchange Act of 1934. This move indicates that the company, which is listed under the ticker symbol “NBSE,” has fewer than 300 shareholders of record and, therefore, is no longer required to report its financial results and other information with the SEC. This filing can result from various reasons, such as a decrease in the number of shareholders or a strategic decision to reduce regulatory obligations.
NeuBase Therapeutics, Inc. is a biotechnology company focused on developing next-generation gene silencing therapies to address genetic diseases. By utilizing its proprietary PATrOL™ platform, the company aims to create highly specific therapies that can modulate the genetic mutations underlying various conditions. NeuBase’s innovative approach has the potential to revolutionize the treatment of diseases with a genetic component, offering new hope to patients and healthcare providers. For more information about NeuBase Therapeutics, Inc., please visit their website at https://www.neubasetherapeutics.com/.
Form 15-12G is a filing with the SEC that publicly-traded companies submit to terminate their registration of a class of securities under Section 12(g) of the Securities Exchange Act of 1934. This form is typically used when a company no longer meets the requirements for mandatory registration and reporting with the SEC, such as having fewer than 300 shareholders of record. Once approved by the SEC, the company is relieved of its reporting obligations, allowing it to operate with fewer regulatory burdens.
Read More:
NeuBase Therapeutics, Inc. Files Form 15-12G with the SEC
Leave a Reply